Subject(s)
Drug-Related Side Effects and Adverse Reactions/etiology , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Trimethoprim/adverse effects , Adult , Drug Interactions , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/urine , Female , Humans , Protein Binding , Trimethoprim/pharmacokinetics , Trimethoprim/urine , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacokineticsABSTRACT
Elimination of pharmaceuticals in source-separated human urine is a promising approach to minimize the pharmaceuticals in the environment. Although the degradation kinetics of pharmaceuticals by UV/H2O2 and UV/peroxydisulfate (PDS) processes has been investigated in synthetic fresh and hydrolyzed urine, comprehensive evaluation of the advanced oxidation processes (AOPs), such as product identification and toxicity testing, has not yet been performed. This study identified the transformation products of two commonly used antibiotics, trimethoprim (TMP) and sulfamethoxazole (SMX), by UV/H2O2 and UV/PDS in synthetic urine matrices. The effects of reactive species, including â¢OH, SO4(â¢-), CO3(â¢-), and reactive nitrogen species, on product generation were investigated. Multiple isomeric transformation products of TMP and SMX were observed, especially in the reaction with hydroxyl radical. SO4(â¢-) and CO3(â¢-) reacted with pharmaceuticals by electron transfer, thus producing similar major products. The main reactive species deduced on the basis of product generation are in good agreement with kinetic simulation of the advanced oxidation processes. A strain identified as a polyphosphate-accumulating organism was used to investigate the antimicrobial activity of the pharmaceuticals and their products. No antimicrobial property was detected for the transformation products of either TMP or SMX. Acute toxicity employing luminescent bacterium Vibrio qinghaiensis indicated 20-40% higher inhibitory effect of TMP and SMX after treatment. Ecotoxicity was estimated by quantitative structure-activity relationship analysis using ECOSAR.
Subject(s)
Hydrogen Peroxide/chemistry , Sulfamethoxazole/urine , Sulfates/chemistry , Trimethoprim/urine , Ultraviolet Rays , Aeromonas/drug effects , Anti-Infective Agents/pharmacology , Carbonates/chemistry , Free Radicals/chemistry , Humans , Hydrogen Peroxide/pharmacology , Hydroxyl Radical/chemistry , Kinetics , Microbial Sensitivity Tests , Oxidation-Reduction , Photolysis/radiation effects , Reactive Nitrogen Species/chemistry , Solutions , Sulfamethoxazole/pharmacology , Toxicity Tests, Acute , Vibrio/drug effectsABSTRACT
Aditoprim (ADP) is a newly developed antibacterial agent in veterinary medicine. The metabolism and disposition of ADP in swine, broilers, carp and rats were investigated by using a radio tracer method combined with a radioactivity detector and a liquid chromatography/ion trap/time-of-flight mass spectrometry. After a single oral administration, more than 94% of the dose was recovered within 14 d in the four species. The urine excretion was dominant in swine and rats, making up 78% of the dose. N-monodesmethyl-ADP, N-didesmethyl-ADP, and 10 new metabolites were characterized. These metabolites were biotransformed from the process of demethylation, α-hydroxylation, N-oxidation, and NH2-glucuronidation. After an oral dose for 7 d, ADP-derived radioactivity was widely distributed in tissues, and high concentrations were especially observed in bile, liver, kidney, lung, and spleen. The radioactivity in the liver was eliminated much more slowly than in other tissues, with a half-life of 4.26, 3.38, 6.69, and 5.21 d in swine, broilers, carp, and rats, respectively. ADP, N-monodesmethyl-ADP, and N-didesmethyl-ADP were the major metabolites in edible tissues. Notably, ADP was detected with the highest concentration and the longest duration in these tissues. These findings indicated that ADP is the marker residue and the liver is the residue target tissue.
Subject(s)
Adenosine Diphosphate/metabolism , Liver/chemistry , Trimethoprim/analogs & derivatives , Administration, Oral , Animals , Carps/urine , Chickens/urine , Chromatography, Liquid , Mass Spectrometry , Rats/urine , Swine/urine , Tissue Distribution , Trimethoprim/administration & dosage , Trimethoprim/pharmacokinetics , Trimethoprim/urineABSTRACT
Through precipitation polymerization, three monodisperse molecularly imprinted polymers (MIPs) containing imprints of 2,4-diamino-6-methyl-1,3,5-triazine (DM), cyromazine (CY) or trimethoprim (TM), were synthesized using methacrylic acid as functional monomer, divinylbenzene as cross-linker, and a mixture of acetonitrile-toluene (90/10, v/v) as porogen. The morphology and selectivity of the MIPs were characterized and compared systematically. The MIPs had the best specific binding in pure acetonitrile, and the data of adsorption experiment were fitted well with Langmuir and Freundlich model. In addition, DM-MIPs showed the excellent binding and multi-recognition capability for CY, melamine (ME), triamterene (TA) and TM, and the binding capacity were 7.18, 7.56, 5.66 and 5.45µmol/g, respectively. Due to the pseudo template and the ability of multi-recognition, DM-MIPs as sorbent material could avoid the effect of template leakage on quantitative analysis. Therefore, DM-MIPs were used as a solid-phase extraction material to enrich ME, CY, TA and TM from different bio-matrix samples for high performance liquid chromatography analysis. Under the optimized conditions, the recoveries of three spiked levels in different bio-matrix samples were ranged from 80.9% to 91.5% with RSD≤4.2 (n=3).
Subject(s)
Microspheres , Polymerization , Triamterene/isolation & purification , Triazines/isolation & purification , Trimethoprim/isolation & purification , Humans , Limit of Detection , Microscopy, Electron, Scanning , Triamterene/urine , Triazines/urine , Trimethoprim/urineABSTRACT
In eThekwini, South Africa, the production of agricultural fertilizers from human urine collected from urine-diverting dry toilets is being evaluated at a municipality scale as a way to help finance a decentralized, dry sanitation system. The present study aimed to assess a range of human and environmental health hazards in source-separated urine, which was presumed to be contaminated with feces, by evaluating the presence of human pathogens, pharmaceuticals, and an antibiotic resistance gene. Composite urine samples from households enrolled in a urine collection trial were obtained from urine storage tanks installed in three regions of eThekwini. Polymerase chain reaction (PCR) assays targeted 9 viral and 10 bacterial human pathogens transmitted by the fecal-oral route. The most frequently detected viral pathogens were JC polyomavirus, rotavirus, and human adenovirus in 100%, 34% and 31% of samples, respectively. Aeromonas spp. and Shigella spp. were frequently detected gram negative bacteria, in 94% and 61% of samples, respectively. The gram positive bacterium, Clostridium perfringens, which is known to survive for extended times in urine, was found in 72% of samples. A screening of 41 trace organic compounds in the urine facilitated selection of 12 priority pharmaceuticals for further evaluation. The antibiotics sulfamethoxazole and trimethoprim, which are frequently prescribed as prophylaxis for HIV-positive patients, were detected in 95% and 85% of samples, reaching maximum concentrations of 6800 µg/L and 1280 µg/L, respectively. The antiretroviral drug emtricitabine was also detected in 40% of urine samples. A sulfonamide antibiotic resistance gene (sul1) was detected in 100% of urine samples. By coupling analysis of pathogens and pharmaceuticals in geographically dispersed samples in eThekwini, this study reveals a range of human and environmental health hazards in urine intended for fertilizer production. Collection of urine offers the benefit of sequestering contaminants from environmental release and allows for targeted treatment of potential health hazards prior to agricultural application. The efficacy of pathogen and pharmaceutical inactivation, transformation or removal during urine nutrient recovery processes is thus briefly reviewed.
Subject(s)
Anti-Bacterial Agents/urine , Antiviral Agents/urine , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/isolation & purification , Urine/microbiology , Urine/virology , Anti-Bacterial Agents/isolation & purification , Antiviral Agents/isolation & purification , Drug Resistance, Microbial/genetics , Emtricitabine/isolation & purification , Emtricitabine/urine , Health Impact Assessment , Humans , South Africa , Sulfamethoxazole/isolation & purification , Sulfamethoxazole/urine , Trimethoprim/isolation & purification , Trimethoprim/urineABSTRACT
The antimicrobial trimethoprim-sulfamethoxazole (TMP-SMX) is widely used for the treatment of skin and soft-tissue infections in the outpatient setting. Despite its therapeutic benefits, TMP-SMX has been associated with a number of adverse drug reactions, which have been primarily attributed to the formation of reactive metabolites from SMX. Recently, in vitro experiments have demonstrated that TMP may form reactive intermediates as well. However, evidence of TMP bioactivation in patients has not yet been demonstrated. In this study, we performed in vitro trapping experiments with N-acetyl-l-cysteine (NAC) to determine stable markers of reactive TMP intermediates, focusing on eight potential markers (NAC-TMP adducts), some of which were previously identified in vitro. We developed a specific and sensitive assay involving liquid chromatography followed by tandem mass spectrometry for measurement of these adducts in human liver microsomal samples and expanded the methodology toward the detection of these analytes in human urine. Urine samples from four patients receiving TMP-SMX treatment were analyzed, and all samples demonstrated the presence of six NAC-TMP adducts, which were also detected in vitro. These adducts are consistent with the formation of imino-quinone-methide and para-quinone-methide reactive intermediates in vivo. As a result, the TMP component of TMP-SMX should be considered as well when evaluating adverse drug reactions to TMP-SMX.
Subject(s)
Anti-Infective Agents/pharmacokinetics , Trimethoprim, Sulfamethoxazole Drug Combination/pharmacokinetics , Trimethoprim/pharmacokinetics , Acetylcysteine/metabolism , Anti-Infective Agents/pharmacology , Anti-Infective Agents/urine , Biomarkers/urine , Biotransformation , Child , Child, Preschool , Chromatography, Liquid , Humans , Microsomes, Liver/metabolism , Tandem Mass Spectrometry , Trimethoprim/pharmacology , Trimethoprim/urine , Trimethoprim, Sulfamethoxazole Drug Combination/urineABSTRACT
Because of the increasing bacterial resistance of uropathogens against standard antibiotics, such as trimethoprim (TMP), older antimicrobial drugs, such as nitroxoline (NTX), should be reevaluated. This randomized crossover study investigated the urinary concentrations of parent drugs and their metabolites and their antibacterial activities (urinary inhibitory titers [UITs] and urinary bactericidal titers [UBTs]) against uropathogens at three different urinary pH values within 24 h in six healthy volunteers after a single oral dose of NTX at 250 mg versus TMP at 200 mg. In three additional volunteers, urinary bactericidal kinetics (UBK) were studied after oral administration of NTX at 250 mg three times a day. The mean urinary concentrations of NTX and NTX sulfate in 24 h were 0.012 to 0.507 mg/liter and 0.28 to 27.83 mg/liter, respectively. The mean urinary concentrations of TMP were 18.79 to 41.59 mg/liter. The antibacterial activity of NTX was higher in acidic urine than in alkaline urine, and that of TMP was higher in alkaline urine than in acidic urine. The UITs and UBTs of NTX were generally lower than those of TMP except for a TMP-resistant Escherichia coli strain, for which NTX showed higher UITs/UBTs than did TMP. UBK showed mainly bacteriostatic activity of NTX in urine. NTX exhibits mainly bacteriostatic activity and TMP also shows bactericidal activity in urine against susceptible strains. NTX is a more active antibacterial in acidic urine, and TMP is more active in alkaline urine. The cumulative effects of multiple doses or inhibition of bacterial adherence could not be evaluated. (This study has been registered at EudraCT under registration no. 2009-015631-32.).
Subject(s)
Anti-Bacterial Agents/urine , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Nitroquinolines/urine , Proteus mirabilis/drug effects , Staphylococcus saprophyticus/drug effects , Trimethoprim/urine , Anti-Bacterial Agents/pharmacokinetics , Bacterial Infections , Cross-Over Studies , Drug Administration Schedule , Escherichia coli/growth & development , Healthy Volunteers , Humans , Hydrogen-Ion Concentration , Klebsiella pneumoniae/growth & development , Microbial Sensitivity Tests , Nitroquinolines/pharmacokinetics , Proteus mirabilis/growth & development , Staphylococcus saprophyticus/growth & development , Trimethoprim/pharmacokinetics , Urinary Tract InfectionsABSTRACT
PURPOSE: Prophylactic antibiotics are commonly used to prevent urinary tract infections in children with conditions such as vesicoureteral reflux. Patient compliance with antibiotics is salient, given the effects that noncompliance can have on development of antibiotic resistance and outcomes of clinical trials. Prior series have shown variable compliance (17% to 70%). However, no study has used objective methods. We hypothesized that direct measurement of urine antibiotic levels can reveal poor compliance. MATERIALS AND METHODS: During a pediatric urology clinic visit patients 0 to 18 years old taking trimethoprim prophylaxis for any urological diagnosis were invited to participate in the study. They were unaware of any potential urine testing before the visit. Urine was sent for chromatography to quantify trimethoprim levels. Parents also completed a compliance self-assessment. RESULTS: Of patients invited to participate 97% consented (54 patients). Of the patients 91% were compliant based on urine levels. Factors not associated with compliance included age, gender, self-report of compliance, duration of time on antibiotics, insurance status and history of breakthrough infection, surgery, pyelonephritis or hospitalization. CONCLUSIONS: This study demonstrates the highest compliance reported for children taking prophylactic antibiotics to prevent urinary tract infection. We attribute this unexpected result to the discussion by specialists of 1 problem for the duration of an office visit. All education in this study was part of clinical care. Thus, our results should be generalizable to nonstudy environments. Future studies should confirm whether this high level of compliance can be achieved by nephrologists and pediatricians. If such compliance cannot be achieved at nonsurgical clinics, then early referral to a pediatric urologist may be warranted.
Subject(s)
Anti-Bacterial Agents/urine , Antibiotic Prophylaxis , Patient Compliance , Trimethoprim/urine , Urinary Tract Infections/prevention & control , Ambulatory Care , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Infant , Male , Prospective Studies , Single-Blind Method , Trimethoprim/therapeutic useABSTRACT
Diet is purported to be means of exposure to many environmental contaminants. The purpose of this study is to understand the influence of dietary change on the levels of exposure to several environmental chemicals - in particular, antibiotics and phthalates. For this purpose, we examined the extent to which short-term changes in diet influenced the inadvertent exposure levels to these chemicals in an adult population. We recruited participants (n=25) of a five-day 'Temple Stay' program in Korea and collected urine samples before and after the program. We also conducted a questionnaire survey on participants' dietary patterns prior to their participation. During the program, participants followed the daily routines of Buddhist monks and maintained a vegetarian diet. Urinary levels of three antibiotics and their major metabolites, metabolites of four major phthalates, and malondialdehyde (MDA) as an oxidative stress biomarker were analyzed. The frequency and levels of detection for antibiotics and phthalates noticeably decreased during the program. Urinary MDA levels were significantly lower than before program participation (0.16 versus 0.27mg/g creatinine). Although the exposure to target compounds might be influenced by other behavioral patterns, these results suggest that even short-term changes in dietary behavior may significantly decrease inadvertent exposure to antibiotics and phthalates and hence may reduce oxidative stress levels.
Subject(s)
Anti-Bacterial Agents/urine , Diet, Vegetarian , Environmental Exposure/analysis , Phthalic Acids/urine , Adult , Dibutyl Phthalate/analogs & derivatives , Dibutyl Phthalate/urine , Enrofloxacin , Female , Fluoroquinolones/urine , Humans , Male , Malondialdehyde/urine , Oxidative Stress , Sulfamethazine/urine , Thiobarbituric Acid Reactive Substances/metabolism , Trimethoprim/urine , Young AdultABSTRACT
OBJECTIVE: The effect of trimethoprim, a potent organic cation transport inhibitor, on the pharmacokinetics (PK) of paliperidone extended-release tablets (paliperidone ER), an organic cation mainly eliminated via renal excretion, was assessed. METHODS: Open-label, two-period, randomized, crossover study in 30 healthy males. Single dose of paliperidone ER 6 mg was administered either alone on day 1 or day 5 during an 8-day treatment period of trimethoprim 200 mg twice daily. Serial blood and urine samples were collected for PK and plasma protein binding of paliperidone and its enantiomers. The 90% confidence interval (CI) of ratios with/without trimethoprim for PK parameters of paliperidone and its enantiomers calculated. RESULTS: Creatinine clearance decreased from 119 to 102 mL min(-1) with trimethoprim. Addition of trimethoprim increased unbound fraction of paliperidone by 16%, renal clearance by 13%, AUC(infinity) by 9%, and t((1/2)) by 19%. The 90% CIs for ratios with/without trimethoprim were within the 80-125% range for C(max), AUC(last), and renal clearance. For AUC(infinity), 90% CI was 79.37-101.51, marginally below the lower bound of the acceptance range. Paliperidone did not affect steady-state plasma concentrations of trimethoprim. CONCLUSIONS: No clinically important drug interactions are expected when paliperidone ER is administered with organic cation transport inhibitors.
Subject(s)
Antipsychotic Agents/pharmacokinetics , Folic Acid Antagonists/pharmacokinetics , Isoxazoles/pharmacokinetics , Pyrimidines/pharmacokinetics , Trimethoprim/pharmacokinetics , Adult , Analysis of Variance , Antipsychotic Agents/blood , Antipsychotic Agents/urine , Area Under Curve , Cross-Over Studies , Drug Administration Schedule , Drug Delivery Systems , Drug Interactions , Electrocardiography/methods , Folic Acid Antagonists/blood , Folic Acid Antagonists/urine , Heart Rate/drug effects , Heart Rate/physiology , Humans , Isoxazoles/blood , Isoxazoles/urine , Male , Middle Aged , Paliperidone Palmitate , Pyrimidines/blood , Pyrimidines/urine , Single-Blind Method , Time Factors , Trimethoprim/blood , Trimethoprim/urine , Young AdultABSTRACT
PURPOSE: The role of crystal habit in influencing the physical stability and pharmacokinetics of trimethoprim suspensions was examined. METHODS: Different habits for trimethoprim (TMP) were obtained by recrystallizing the commercial sample (PD) utilizing solvent-change precipitation method. Four distinct habits (microscopic observation) belonging to the same polymorphic state (DSC studies) were selected for studies. Preformulation and formulation studies were carried out on suspension dosage forms containing these crystals. The freshly prepared suspensions were also evaluated for their pharmacokinetic behaviour on healthy human volunteers using a cross over study. RESULTS: Variation of crystallization conditions produces different habits of TMP. Among the different crystal habits exhibiting same polymorphic state, the most anisometric crystal showed best physical stability in terms of sedimentation volume and redispersibility. However, habit did not significantly affect the extent of TMP excreted in urine. CONCLUSIONS: Modification of surface morphology without significantly altering the polymorphic state can be utilized for improving physical stability of TMP suspensions. However, the pharmacokinetic profile remains unaltered.
Subject(s)
Crystallization , Trimethoprim/chemistry , Adult , Biological Availability , Chemistry, Pharmaceutical , Drug Stability , Humans , Male , Trimethoprim/pharmacokinetics , Trimethoprim/urineABSTRACT
Hypersensitivity reactions from trimethoprim/sulfamethoxazole are likely caused by a reactive nitroso intermediate formed from sulfamethoxazole hydroxylamine. This pilot study tested whether cimetidine inhibits the urinary excretion of sulfamethoxazole hydroxylamine. Ten outpatients infected with human immunodeficiency virus (HIV) and currently receiving trimethoprim/sulfamethoxazole prophylaxis were randomly selected from 59 eligible patients. Five received cimetidine 800 mg twice daily for 1 week and five served as controls. Two spot urine samples one week apart were obtained after a trimethoprim/sulfamethoxazole dose for all patients. Patients taking cimetidine had a significant decrease in excretion of sulfamethoxazole hydroxylamine relative to total excreted drug in the two urine samples compared with control patients. Cimetidine likely caused this decrease in sulfamethoxazole hydroxylamine excretion through inhibition of CYP3A4. Because of potential differences between HIV-infected patients and healthy subjects in oxidative metabolism, future studies of inhibitors of sulfamethoxazole hydroxylamine formation should be conducted in the HIV population.
Subject(s)
Anti-Ulcer Agents/pharmacology , Cimetidine/pharmacology , HIV Infections/metabolism , Sulfamethoxazole/analogs & derivatives , Adult , Anti-Infective Agents/metabolism , Anti-Infective Agents/urine , Antibiotic Prophylaxis , Double-Blind Method , Drug Interactions , Female , HIV Infections/urine , Humans , Male , Pilot Projects , Sulfamethoxazole/metabolism , Sulfamethoxazole/urine , Trimethoprim/metabolism , Trimethoprim/urineABSTRACT
The use of coupled solid-phase extraction and high-field proton nuclear magnetic resonance spectroscopy (SPE-1HNMR) for the detection and identification of the urinary metabolites of brodimoprim is described. Urine was obtained from Wistar rats following a dose of 200 mg.kg-1 of brodimoprim. Analysis was performed on partially purified extracts obtained by solid-phase extraction onto C-18 bonded silica gel. As each spectrum was often given by a mixture of more than two kinds of metabolites, stepwise identification of the individual metabolites was achieved by sorting out signal sets having invariant proportionality. Five kinds of metabolites of the drug were found by the analysis.
Subject(s)
Trimethoprim/analogs & derivatives , Trimethoprim/metabolism , Animals , Magnetic Resonance Spectroscopy/methods , Male , Rats , Rats, Wistar , Trimethoprim/chemistry , Trimethoprim/urineABSTRACT
The pharmacokinetics of brodimoprim have been investigated after single oral dose administration in children, in healthy adults, and elderly subjects, as well as in patients with mild renal failure (creatinine clearance 40-70 mL/min) or liver insufficiency (Child-Pugh grade A or B). The plasma half-life increased moderately with age. The percent brodimoprim bound to plasma proteins, 93%, was identical in renally impaired patients and in healthy controls but decreased to 90% or less in liver insufficiency. The apparent distribution volume and clearance were much higher in children than in adults. Urinary excretion of unchanged brodimoprim amounted to 5-10% of the administered dose. The steady-state pharmacokinetics of brodimoprim has also been investigated in elderly subjects (400 mg loading dose followed by 7 days 200 mg once daily). There was no significant modification of elimination half-life and of clearance upon repeated dosing. Renal excretion of brodimoprim and hydroxy metabolite at steady-state reached 9% and 14% per 24 hours in the elderly, compared to 9% and 24% in young adults. The accumulation factor reached 3.3 +/- 0.4 and 2.7 +/- 0.3 respectively.
Subject(s)
Liver Diseases/metabolism , Renal Insufficiency/metabolism , Trimethoprim/analogs & derivatives , Adult , Aged , Aged, 80 and over , Aging/blood , Aging/metabolism , Aging/urine , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Half-Life , Humans , Liver Diseases/blood , Liver Diseases/urine , Male , Middle Aged , Renal Insufficiency/blood , Renal Insufficiency/urine , Trimethoprim/blood , Trimethoprim/pharmacokinetics , Trimethoprim/urineABSTRACT
A high-performance liquid chromatographic method was developed to measure the concentration of brodimoprim and its metabolite, hydroxybrodimoprim, in small volumes of blood, plasma and urine. The procedure involved a simple extraction step with chloroform, followed by chromatographic separation on a short reversed-phase column deactivated for the analysis of basic compounds. The column effluent was monitored by fluorescence (excitation wavelength 290 nm, emission wavelength 340 nm). The recoveries of both compounds were similar in all three biological fluids, and averaged 84 and 72%, respectively. The detection limit for both compounds reached 5 ng/ml. No endogenous compound interfered in the assay. The linearity of the method and its within- and between-day precision were analytically satisfactory.
Subject(s)
Chromatography, High Pressure Liquid/methods , Trimethoprim/analogs & derivatives , Humans , Reproducibility of Results , Spectrometry, Fluorescence , Trimethoprim/analysis , Trimethoprim/blood , Trimethoprim/urineABSTRACT
Two oral pharmaceutical formulations (URO-TS D and Bactrim F) containing 800 mg of sulfamethoxazole (SMZ) and 160 mg of trimethoprim (TMP) were given to 10 Mexican healthy volunteers, following a randomized cross-over design. Blood and urine samples were obtained, concentrations of TMP, SMZ, and its metabolite N4-acetyl SMZ were measured by HPLC and pharmacokinetic analyses were performed. The observed Cmax, tmax, half-life, AUC, and cumulative urinary excretion values for the three compounds studied were within the ranges that have been previously reported for European and North American subjects. Therefore, it appears that pharmacokinetics of SMZ and TMP in Mexicans are similar to those observed in Caucasian populations. When the two studied formulations were compared, no statistically significant differences were detected in any pharmacokinetic parameter. Therefore, it is concluded that both brands tested are bioequivalent. Moreover, these two formulations manufactured in Mexico yield SMZ and TMP plasma and urine levels similar to those obtained with equivalent formulations of European or North American origin.
Subject(s)
Sulfamethoxazole/pharmacokinetics , Trimethoprim/pharmacokinetics , Adult , Humans , Male , Mexico , Random Allocation , Sulfamethoxazole/blood , Sulfamethoxazole/urine , Therapeutic Equivalency , Trimethoprim/blood , Trimethoprim/urineABSTRACT
Procedures for the simultaneous determination of trimethoprim (TMP) and sulfamethoxazole (SMX) in plasma or urine are reported. The drugs are extracted from plasma or urine by a single solid-phase extraction and quantitated by high-performance liquid chromatography. Both drugs are analyzed in the same chromatographic run. Intra- and interassay variability are less than 10% for both compounds, and the recovery and precision of TMP measurement are unaffected by concurrent SMX concentrations. Limits of quantitation for TMP and SMX in plasma were 0.02 and 0.21 microgram/ml, respectively. In urine, the limit of quantitation for both drugs was 1.0 microgram/ml. Metabolites of TMP and SMX did not interfere with the assay. Pharmacokinetic parameters from volunteers given two formulations of co-trimoxazole in a crossover comparison study are reported.
Subject(s)
Sulfamethoxazole/analysis , Trimethoprim/analysis , Biological Availability , Chromatography, High Pressure Liquid/methods , Humans , Reproducibility of Results , Spectrophotometry, Ultraviolet/methods , Sulfamethoxazole/blood , Sulfamethoxazole/pharmacokinetics , Sulfamethoxazole/urine , Trimethoprim/blood , Trimethoprim/pharmacokinetics , Trimethoprim/urineABSTRACT
Six healthy adult mares were each given a single IV injection of trimethoprim (TMP)-sulfamethoxazole (SMZ) at a dosage of 2.5 mg of TMP/kg of body weight and 12.5 mg of SMZ/kg. Serum concentrations of each drug were measured serially over a 24-hour period. For TMP, the mean overall elimination rate constant (K) was 0.43/hr and the elimination half-life (t1/2) was 1.9 hours. The apparent volume of distribution (at steady state) was 1.62 L/kg and TMP clearance was 886 ml/hr/kg. For SMZ, K was 0.22/hr and t1/2 was 3.53 hours. The apparent volume of distribution at steady state was 0.33 L/kg and SMZ clearance was 78.2 ml/hr/kg. Each mare was then given 5 consecutive oral doses of TMP-SMZ at a rate of 2.5 mg of TMP/kg and 12.5 mg of SMZ/kg at 12-hour intervals. Trimethoprim and SMZ concentrations were measured in serum, synovial fluid, peritoneal fluid, CSF, urine, and endometrium. Although both mean TMP and SMZ serum concentrations were higher after the 5th dose than after the 1st dose, only the mean TMP concentration was significantly (P less than 0.05) different. After the 5th oral dose, concentrations of TMP and SMZ attained in body fluids (except CSF) and endometrial tissue were equal to or exceeded reported minimum inhibitory concentrations for Corynebacterium pseudotuberculosis, Staphylococcus sp, Streptococcus zooepidemicus, and several obligate anaerobes. Absorption of both drugs was variable after oral administration.